Developing long-acting growth hormone formulations

Clinical Endocrinology

Volumn 79, Issue 3, 2013, Pages 305-309

  Cawley, Pippa ^a   Wilkinson, Ian ^a   Ross, Richard J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACP 001; ALBUTROPIN; HUMAN GROWTH HORMONE; MOD 4023; NNC 126 0083; NNC126 0083; RECOMBINANT GROWTH HORMONE; UNCLASSIFIED DRUG; VRS 317;

BINDING SITE; DRUG FORMULATION; ENCAPSULATION; GROWTH HORMONE RELEASE; HUMAN; INJECTION SITE ERYTHEMA; LIPOATROPHY; LONG TERM EXPOSURE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUSPENSION;

EID: 84880836617     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12240     Document Type: Review

References (32)

1. Achermann, J.C., Brook, C.G., Robinson, I.C., et al,. (1999) Peak and trough growth hormone (GH) concentrations influence growth and serum insulin like growth factor-1 (IGF-1) concentrations in short children. Clinical Endocrinology, 50, 301-308.
2. Gevers, E.F., Wit, J.M., &, Robinson, I.C., (1996) Growth, growth hormone (GH)-binding protein, and GH receptors are differentially regulated by peak and trough components of the GH secretory pattern in the rat. Endocrinology, 137, 1013-1018.
3. Westwood, M., Maqsood, A.R., Solomon, M., et al,. (2010) The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat. American Journal of Physiology Endocrinology and Metabolism, 298, E467-E476.
4. Jorgensen, J.O., Moller, J., Moller, N., et al,. (1990) Pharmacological aspects of growth hormone replacement therapy: route, frequency and timing of administration. Hormone Research, 33 (Suppl 4), 77-82.
5. Jorgensen, J.O., Blum, W.F., Moller, N., et al,. (1991) Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients. Journal of Clinical Endocrinology & Metabolism, 72, 582-587.
6. Jorgensen, J.O., Moller, N., Lauritzen, T., et al,. (1990) Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. Journal of Clinical Endocrinology & Metabolism, 70, 1616-1623.
7. Laursen, T., Gravholt, C.H., Heickendorff, L., et al,. (2001) Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 86, 1222-1228.
8. Smith, S.L., Hindmarsh, P.C., &, Brook, C.G., (1995) Compliance with growth hormone treatment-are they getting it? Archives of Disease in Childhood, 73, 277.
9. Rosenfeld, R.G., &, Bakker, B., (2008) Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 14, 143-154.
10. Cutfield, W.S., Derraik, J.G., Gunn, A.J., et al,. (2011) Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS ONE, 6, e16223.
11. Kapoor, R.R., Burke, S.A., Sparrow, S.E., et al,. (2008) Monitoring of concordance in growth hormone therapy. Archives of Disease in Childhood, 93, 147-148.
12. Cook, D.M., Biller, B.M., Vance, M.L., et al,. (2002) The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. The Journal of Clinical Endocrinology and Metabolism, 87, 4508-4514.
13. Kemp, S.F., Fielder, P.J., Attie, K.M., et al,. (2004) Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. The Journal of Clinical Endocrinology and Metabolism, 89, 3234-3240.
14. Hoffman, A.R., Biller, B.M., Cook, D., et al,. (2005) Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. The Journal of Clinical Endocrinology and Metabolism, 90, 6431-6440.
15. Silverman, B.L., Blethen, S.L., Reiter, E.O., et al,. (2002) A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. Journal of Pediatric Endocrinology & Metabolism: JPEM, 15 (Suppl 2), 715-722.
16. Kim, S.J., Hahn, S.K., Kim, M.J., et al,. (2005) Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. Journal of Controlled Release: Official Journal of the Controlled Release Society, 104, 323-335.
17. Bidlingmaier, M., Kim, J., Savoy, C., et al,. (2006) Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. The Journal of Clinical Endocrinology and Metabolism, 91, 2926-2930.
18. Peter, F., Savoy, C., Ji, H.J., et al,. (2009) Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. European Journal of Endocrinology/European Federation of Endocrine Societies, 160, 349-355.
19. Biller, B.M., Ji, H.J., Ahn, H., et al,. (2011) Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 96, 1718-1726.
20. Biller, B.M., Ji, H.J., Ahn, H., et al,. (2012) 12-Month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency. Pituitary.
21. Peter, F., Bidlingmaier, M., Savoy, C., et al,. (2012) Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). The Journal of Clinical Endocrinology and Metabolism, 97, 400-407.
22. Touraine, P., D'Souza, G.A., Kourides, I., et al,. (2009) Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. European Journal of Endocrinology, 161, 533-540.
23. Rasmussen, M.H., Jensen, L., Anderson, T.W., et al,. (2010) Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile. Clinical Endocrinology (Oxford), 73, 769-776.
24. Sondergaard, E., Klose, M., Hansen, M., et al,. (2011) Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 96, 681-688.
25. de Schepper, J., Rasmussen, M.H., Gucev, Z., et al,. (2011) Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. European Journal of Endocrinology/European Federation of Endocrine Societies, 165, 401-409.
26. Hoybye, C.P., Pfeiffer, A., Ferone, D., et al,. (2012) A Phase 2, Multiple-Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients with Growth Hormone Deficiency (AGHD). Growth Hormone and IGF Research, 22, S8-S9.
27. Osborn, B.L., Sekut, L., Corcoran, M., et al,. (2002) Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. European Journal of Pharmacology, 456, 149-158.
28. Popovic, V.G., Goth, M.I., Vangua, P., et al,. (2012) Once-weekly, CTP-modified hGH (MOD-4023) Is effective in growth hormone deficient adults: a Phase II, dose and frequency finding study. Endocrine Reviews, 33, OR29-5.
29. Cleland, J.L., Geething, N.C., Moore, J.A., et al,. (2012) A novel long-acting human growth hormone fusion protein (vrs-317): enhanced in vivo potency and half-life. Journal of Pharmaceutical Sciences, 101, 2744-2754.
30. Bailey, T.B., Biller, B., Conway, G., et al,. (2012) A Phase 1 Trial of Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of a New Human Growth Hormone Analogue (VRS-317) for Monthly Subcutaneous Administration in Adults with Growth Hormone Deficiency. Endocrine Reviews, 33, OR29-3.
31. Wilkinson, I.R., Ferrandis, E., Artymiuk, P.J., et al,. (2007) A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. Nature Medicine, 13, 1108-1113.
32. Ferrandis, E., Pradhananga, S.L., Touvay, C., et al,. (2010) Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions. Clinical Science (London), 119, 483-491.